Galapagos NV is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action.
Company profile
Ticker
GLPG, GLPGF
Exchange
Website
CEO
Paul Stoffels
Employees
Location
Fiscal year end
Industry (SIC)
SEC CIK
GLPG stock data
Latest filings (excl ownership)
6-K
Galapagos reports first quarter 2024 financial results
3 May 24
6-K
Current report (foreign)
1 May 24
6-K
Galapagos’ shareholders adopt all resolutions proposed by the Board of Directors at the Annual and Extraordinary Shareholders Meetings 2024
30 Apr 24
6-K
Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024
8 Apr 24
6-K
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
29 Mar 24
6-K
Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board
29 Mar 24
20-F
2023 FY
Annual report (foreign)
28 Mar 24
6-K
Galapagos announces full year 2023 results and outlook for 2024
23 Feb 24
6-K
Galapagos presents at EBMT-EHA annual meeting 2024
16 Feb 24
6-K
Galapagos completes transaction to transfer Jyseleca® business to Alfasigma
6 Feb 24
Latest ownership filings
SC 13D/A
GILEAD SCIENCES, INC.
2 May 24
SC 13G/A
EcoR1 Capital, LLC
14 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
SC 13G
EcoR1 Capital, LLC
7 Jun 23
SC 13G/A
EcoR1 Capital, LLC
14 Feb 23
SC 13G
FMR LLC
9 Feb 23
SC 13G
EcoR1 Capital, LLC
3 Feb 22
SC 13D
VAN HERK INVESTMENTS B.V.
2 Nov 21
SC 13G/A
Capital International Investors
10 May 21
SC 13G/A
Capital International Investors
10 Feb 21
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q4 2023
38.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 7 |
Opened positions | 3 |
Closed positions | 71 |
Increased positions | 1 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 4.16 bn |
Total shares | 25.29 mm |
Total puts | 3.00 k |
Total calls | 3.00 k |
Total put/call ratio | 1.0 |
Largest owners | Shares | Value |
---|---|---|
GILD Gilead Sciences | 20.63 mm | $3.20 bn |
Van Herk Investments B.V. | 4.64 mm | $0.00 |
Moody National Bank Trust Division | 22.52 k | $915.36 mm |
Cacti Asset Management | 1.00 k | $40.61 mm |
Cutler | 345.00 | $14.00 k |
Thrivent Trust Co of Tennessee | 106.00 | $4.00 k |
Planned Solutions | 100.00 | $4.07 mm |
News
Galapagos Q1 EPS €1.40 Vs €0.40 YoY; Revenue €62.4 Million Vs €58.6 Million YoY
2 May 24
Morgan Stanley Maintains Equal-Weight on Galapagos, Maintains $38 Price Target
22 Apr 24
Galapagos Plans Clinical And Translational Data Presentations At EBMT Congress 2024
4 Apr 24
Galapagos Downgraded, Pharma Firm Faces Uphill Battle With Slow Pipeline Progress: Analyst
1 Apr 24
B of A Securities Downgrades Galapagos to Underperform, Lowers Price Target to $31
28 Mar 24
Press releases
Galapagos reports first quarter 2024 financial results
2 May 24
Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024
4 Apr 24
Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board
26 Mar 24
Frontier Medicines Announces Oversubscribed $80 Million Series C Financing to Support Progress of Clinical-Stage Pipeline
22 Feb 24
Galapagos announces full year 2023 results and outlook for 2024
22 Feb 24